Acute Myelogenous Leukemia
The most frequently observed adverse events among patients treated with sorafenib were cytopenias and skin rashes.
There is warranted excitement for AG-221, a drug recently granted fast track designation by the FDA for acute myelogenous leukemia (AML).
The FDA has granted Fast Track designation to AG-221, a first-in-classinhibitor, to treat AML.
Cytogenetic and molecular abnormalities may also be prognostic of post-relapse prognosis.
Results from a new study could benefit some children with high-risk AML. A therapeutic regimen that combined the GO with conventional three-drug chemotherapy was associated with improved survival in children with AML who underwent bone marrow transplantation.
At least one nonsynonymous mutation in a gene relevant for pathogenesis seen in nearly all cases
Assessment of minimal residual disease provides prognostic information for children with AML.
Relapse of acute myeloid leukemia (AML) is associated with acquisition of new mutations and clonal evolution.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC